12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee...Read More 
Share:
12
Nov
2019
Don’t Pull Back on Basic Biology for Psychiatry: It’s Time to Double Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
11
Nov
2019
Disruption, Fast and Slow
Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant...Read More
Share:
7
Nov
2019
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Nov
2019
Tech VCs and Biotech VCs: Talking Past Each Other on AI Drug Discovery
[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech...Read More
Share:
4
Nov
2019
New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
Oct
2019
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
29
Oct
2019
The Story of Henri Termeer: John Hawkins and Jim Geraghty on The Long Run
Today’s guests on The Long Run are John Hawkins and Jim Geraghty. John is a biotech industry veteran and the vice chairman of Odgers Berndtson, an executive recruiting firm in New York. He’s also the author of the new biography on Henri Termeer, the longtime CEO of Genzyme and one of the founding fathers of the biotech industry. Jim Geraghty...Read More
Share:
28
Oct
2019
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Oct
2019
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Oct
2019
Biotech’s film making exec behind ‘Jim Allison: Breakthrough’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Oct
2019
Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
15
Oct
2019
Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run
Today’s guest on The Long Run is Aoife Brennan. Aoife (it’s pronounced EE-fuh in her native Ireland) is the CEO of Synlogic Therapeutics. The company, based in Cambridge, Mass., is trying to build on years of work at MIT in synthetic biology. The basic idea is to create what the company calls Synthetic Biotics, or what you can call “Living...Read More
Share:
10
Oct
2019
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2019
12 VCs Who Matter, But You Hardly Ever Read About
This article was first published on November 20, 2017, then revised and updated October 9, 2019 Vinod Khosla, the tech venture capitalist, has said 95 percent of VCs add zero value to a startup other than cash. About four out of every five VCs, he said, actually damage their own investments with bad advice. When asked to apply the Khosla test...Read More
Share:
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re...Read More
Share:
3
Oct
2019
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Oct
2019
From Farm Field to MIT Lab: Phil Sharp on The Long Run
Today’s guest on The Long Run is Phil Sharp. Phil is one of the world’s most influential biologists and scientific entrepreneurs. Phil won the Nobel Prize in 1993 for his work on RNA splicing. Back in the 1970s in his MIT lab, he looked at the basics of RNA splicing. That paved the way for the discovery of “discontinuous genes.”...Read More
Share:
26
Sep
2019
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Sep
2019
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: